Denali Therapeutics Inc. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-02-11

Reporting Person: Krognes Steve E. (CFO and Treasurer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-11	Common Stock	S	2635	$70.174	Disposed	97987	Direct
2021-02-11	Common Stock	S	400	$71.428	Disposed	97587	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	950000	Indirect

Footnotes

F1: Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.675 to $70.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 80,358 previously reported restricted stock units and 7,285 shares acquired pursuant to vesting of restricted stock units.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.06 to $71.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.